CONTRAINDICATIONS
None.
ADVERSE REACTIONS
The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea, and pruritus.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of Anascorp: chest tightness, palpitations, rash and pruritus.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Severe hypersensitivity reactions, including anaphylaxis, are possible with ANASCORP. Prepare for monitoring and management of allergic reactions, particularly in patients with a history of hypersensitivity to equine (horse) proteins or patients who have received previous therapy with antivenoms containing equine proteins.
Delayed Allergic Reactions (Serum Sickness)
Delayed allergic reactions (serum sickness) may occur following treatment with ANASCORP. Patient monitoring with a follow-up visit is recommended.
Transmissible Infectious Agents
ANASCORP is made from equine plasma and may contain infectious agents, e.g. viruses.
Reaction to Cresol
Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.
See Full Prescribing Information
